The Past and Future of YC Bio

preview_player
Показать описание
Jared Friedman and Surbhi Sarna, YC Group Partners

Рекомендации по теме
Комментарии
Автор

YC is great...Thanks Jared Friedman and Surbhi Sarna for the info..

suryakantpandit
Автор

its one thing to invest in biotech. but your valuations are way off. most preclinical stage bios are not valued at anything $10m or under; with some initial invitro or invivo data depending on indication at minimum its $20M. If you want to really help bios and invest in quality companies then you need to change your valuation perception especially for biotech.

khouse
Автор

The criteria for success are pretty screwed up. How much you raise or valuation rather than old fashioned revenues.

abizarlakdawalla